Incendia Therapeutics
Yan Qin is a professional with experience as a Principal Scientist at Incendia Therapeutics, Fuhong Therapeutics, and Compass Therapeutics Inc. Prior to these roles, Yan was a Research Fellow at Dana-Farber Cancer Institute and Boston Children's Hospital, focusing on LRRC33/GARP and TGF-beta interaction. Yan also studied HIV and DC interaction at Institut Pasteur as a student. Yan holds a PhD in Biotechnology from the Chinese Academy of Sciences and a Bachelor's degree in Biotechnology from Jilin University.
Incendia Therapeutics
Incendia Therapeutics is discovering and developing novel anti-cancer medicines that are designed to reprogram the tumor microenvironment. Many cancers create immune exclusion barriers that prevent the immune system from attacking tumors. The Parthenon approach to overcoming these barriers is to modulate the interplay among cancer cells, stromal cells, and immune cells. Our lead program, PRTH-101, is a first-in-class humanized monoclonal antibody that blocks the interaction of Discoidin Domain Receptor 1 (DDR1) with collagen, thereby “punching holes” in the extracellular matrix barrier created by the tumor. With the extracellular matrix barrier breached, immune cells are able to infiltrate and attack the tumor. PRTH-101 is poised to enter Phase 1 clinical trials. PRTH-101 is followed by a pipeline of preclinical projects targeting orthogonal components of the tumor microenvironment that promote immune exclusion. Incendia combines its drug discovery and development efforts with a precision oncology approach to get the right medicines to the right patients. We use proprietary AI technology to digitally deconstruct the TME and develop unique insights to enable biomarker-driven patient selection strategies designed to guide clinical applications.